Glaxo seeks flu drug approval

Article Abstract:

Glaxo Wellcome PLC, along with its subsidiary, Glaxo Wellcome Inc., based in Mississauga, Canada, has filed for fast-track approval in Europe and Canada, to market the first inhaled drug for the treatment and prevention of influenza. The companies have applied for approval for Relenza, which works by blocking nueraminadise, an enzyme found on the surface of the fluvirus, effectively preventing the virus from spreading the infection from cell to cell. European and Canadian regulatory approvals could make Relenza available by mid-1999, and an application to market the drug in Australia has already been filed, with a corresponding filing with the US Food and Drug Administration slated to follow before end-1998.

Comment:

Has filed for approval in Europe and Canada to market Relenza, an inhaled drug for the treatment and prevention of influenza

Europe, Government regulation (cont), Antiviral Respiratory Preps, Glaxo Wellcome PLC, Antiviral agents, Respiratory system agents, Glaxo Wellcome Inc., Article

Axcan expected to match LHC bid for Scandipharm

Article Abstract:

Montreal, Canada-based Axcan Pharma Inc is expected to up its $85-million offer to purchase Birmingham, AL-based Scandipharm Inc to equal Wilmington, DE-based investment firm LHC Corp's competing offer of $8 per share, or $98 million. Axcan aims to provide Scandipharm shareholders an alternative to LHC's offer by amending its current offer of $7 per share. Shares of Scandipharm, a leading supplier of drugs and nutritional supplements for treating cystic fibrosis, is owned by employees, local investors, management, the founding Wingett family and LHC.

Asset sales & divestitures, Acquisitions & mergers, Open-End Investment Funds, Pharmaceutical Preparations, Alabama, Delaware, Investment Companies, Axcan Pharma Inc., Scandipharm Inc.

Dimethaid stock rises 8% on expectations for arthritis lotion

Article Abstract:

Dimethaid Research Inc's announcement that it will introduce results of phase III clinical test on its topical arthritis lotion Pennsaid at at medical convention in Vienna, Austria, sent the Markham, Ontario-based drug company's stock price up 8%. Results indicated that the group receiving Pennsaid treatment showed statistically significant pain relief. Pennsaid is currently in wait to be approved by regulatory agencies in the US, Canada and the UK.

Product development, Analgesic Ointments, Jellies, Salves, Dimethaid Research Inc., Topical analgesics